NCT02774291 2023-08-04
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
Phase EARLY_PHASE1 Terminated
Clinical Trials
7 trialsNCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01082926 2015-06-08
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
Phase 1 Completed
NCT00002572 2013-05-30
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00004024 2013-04-05
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00003067 2009-02-09
Biological Therapy in Treating Patients With Primary or Advanced Glioma
National Cancer Institute (NCI)
Phase 2 Suspended